ImmunityBioの空売り状況は、投資家がImmunityBioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ImmunityBio (NASDAQ:IBRX) 株価情報, 空売り情報

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？Bilibili Inc.は（NASDAQ：BILI）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、21ドルの株価予測を発表しました。

中国配信大手ビリビリ　株価が23%の高騰

Biotech

Health Care

General

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。 ；腺腫を伴う場合と伴わない場合があります。

FDAはImmunityBioの膀胱癌薬の承認を認め、株価が上昇

月曜日、米食品医薬品局（FDA）はAnktiva（N-803、またはnogapendekinアルファinbakicept-pmln）をツガダケ菌カルメット・ゲレン（BCG）と併用して、原発性非筋層浸潤性膀胱癌（NMIBC）と癌腫内局所性膀胱癌（CIS）に対して承認しました。

ImmunityBio Inc

Barclays analyst Jiong Shao maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Equal-Weight and raises the price target from $82 to $104.

Price Target

Analyst Ratings

NTES

Barclays Maintains Equal-Weight on NetEase, Raises Price Target to $104

Earnings

ICCH

ICC Holdings FY24 EPS $0.54 Vs $0.96 YoY

Shares of aerospace manufacturer and launch service provider Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Monday.
Rocket Lab National Security LLC, a wholly owned subsidiary of Rocket Lab USA, has reached a key milestone with the successful conclusion of the Critical Design Review (CDR) for the <a href="https://www.benzinga.com/pressreleases/25/02/b43910080/rocket-lab-clears-critical-design-review-for-space-force-victus-haze-mission">U.S. Space Force's Space Systems Command </a>(SSC) mission, VICTUS HAZE. 
The VICTUS HAZE mission, led by Space Safari and in collaboration with the Defense Innovation Unit (DIU), aims to quickly deploy a spacecraft capable of performing rendezvous and proximity operations. 
&#8220;The ability to build a spacecraft, launch it, and operate it all in-house, on a tactically responsive timeline, is incredibly rare, but with our extensive launch heritage and deep vertical integration across space systems, we&#8217;re ideally suited to make this mission a success,&#8221; said president and CEO of Rocket Lab National Security, Brad Clevenger.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
&#8220;VICTUS HAZE solidifies Rocket Lab as a trusted and highly capable, end-to-end space company that can enable complex missions to serve the needs of the nation,&#8221; Clevenger added.
This spacecraft is specifically designed to address space-based threats, ensuring launch readiness within 24 hours. Rocket Lab&#8217;s Pioneer spacecraft will be launched aboard the company&#8217;s Electron rocket from Launch Complex 1 in Mahia, New Zealand.
Following the successful CDR, the project advances into the production phase. During this phase, the spacecraft and launch vehicle will be integrated and preparations for the ground segment will begin.
The mission aims to showcase the capability to monitor and intercept objects in orbit, strengthening the U.S. Space Force&#8217;s capacity to rapidly address potential space threats.
Price Action: RKLB shares are trading higher by 0.72% at $23.72 in premarket at last check Monday.
Read Next: <a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
Photo: Shutterstock

Rocket Lab Achieves Critical Design Review For US Space Force Mission

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $9 to $6.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $6

SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>), a transportation safety technology company, has been awarded its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43910063/saverone-granted-new-patent-in-the-united-states-further-expanding-its-ip-portfolio" rel="noreferrer noopener">13th patent</a> by the United States Patent and Trademark Office (USPTO). Issued on February 18, 2025, under patent number 12,231,899, the patent covers SaverOne&#8217;s system designed to restrict mobile phone use while driving.
This patented technology enhances SaverOne&#8217;s in-vehicle safety system by allowing drivers to access only approved applications, such as navigation or calls, while blocking all others. It achieves this through wireless communication between the vehicle&#8217;s Phone Location Unit and the driver&#8217;s mobile device.
Under U.S. law, the patent term is 20 years from the application&#8217;s effective filing date. With this new patent, SaverOne&#8217;s portfolio includes 23 patents, 13 of which have been granted in various jurisdictions and 10 more pending. 
SaverOne CEO Ori Gilboa emphasized that the latest U.S. patent grant further strengthens the company&#8217;s intellectual property portfolio, highlighting the uniqueness and innovation of its technology. He noted that as mobile phone-related distractions continue to pose a major risk to road safety, SaverOne remains dedicated to developing and protecting advanced solutions to help prevent accidents.
Recently, SaverOne&#8217;s U.S. distributor, Motor Supply, successfully completed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43780269/saverone-announces-first-u-s-commercial-agreement-with-fedex-trucking-contractor-mdm-express" rel="noreferrer noopener">pilot with FedEx</a> contractor MDM Express, which led to a full fleet installation. This milestone strengthened SaverOne&#8217;s U.S. expansion and fleet safety impact.
Price Action: SVRE shares are trading higher by 4.62% at $4.31 premarket at the last check Monday.
Image via Shutterstock.

Equities

SVRE

SaverOne Expands IP Portfolio With New US Patent, Stock Gains

WIIM

UNIT

Uniti Group shares are trading higher after Raymond James upgraded its stock rating from outperform to strong buy.

AREC

American Resources shares are trading higher after the company announced it has agreed to source commodities for refinement by ReElement Technologies.

Barclays analyst Matt Miksic maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and raises the price target from $100 to $103.

GMED

Barclays Maintains Overweight on Globus Medical, Raises Price Target to $103

Citizens Capital Markets analyst Patrick Walravens reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Market Outperform and maintains $450 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Salesforce, Maintains $450 Price Target

Contracts

VUZI

Vuzix Announces Fulfillment Of Six-Figure Waveguide Order Placed By A Major U.S. Based Defense Contractor For Defense Heads-Up Display

Barclays analyst Terry Ma maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Equal-Weight and raises the price target from $61 to $67.

Barclays Maintains Equal-Weight on Fidelity National Finl, Raises Price Target to $67

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4367689-1&amp;h=202193409&amp;u=https%3A%2F%2Fsabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>), a leading global travel technology company, and GOL Linhas Aéreas, one of the leading airlines in Brazil, today announced the extension of their long-standing partnership. The renewed agreement includes the continued use of Sabre's Passenger Service System (PSS) and Global Distribution System (GDS), as well as the adoption of Sabre's Mosaic solutions, such as Ancillary IQ&#x2122; and Dynamic Availability, to support GOL's growth and retailing strategies to improve its revenue performance.
By integrating SabreMosaic modules, GOL aims to enhance its retailing capabilities and offer personalized experiences to travelers. Ancillary IQ&#x2122; will enable GOL to provide personalized and optimized ancillary offers by leveraging AI and real-time data to recommend the right products—such as seat upgrades, baggage, and priority boarding—tailored to each traveler. Meanwhile, Dynamic Availability optimizes pricing in real time by intelligently adjusting seat availability and fare conditions based on market demand and airline strategies. Additionally, GOL is implementing Sabre's Self-Service Reaccommodation solution to empower travelers with tailored rebooking options on their mobile devices, enhancing satisfaction and streamlining operations.

SABR

GOL Linhas Aéreas Strengthens Partnership With Sabre, Leveraging SabreMosaic To Boost Revenue

Barclays analyst Nicholas Campanella maintains Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) with a Underweight and raises the price target from $92 to $95.

Barclays Maintains Underweight on Consolidated Edison, Raises Price Target to $95

LQR House shares are trading higher after the company announced a better-than-expected year-over-year revenue decline for its flagship website despite eliminating advertising on Google and Meta.

Unity Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) shares are trading lower Monday after the company announced a proposed offering of <a href="https://www.benzinga.com/pressreleases/25/02/b43908700/unity-announces-proposed-500-0-million-offering-of-convertible-senior-notes">convertible senior notes</a>.
What Happened: Before the market open on Monday, Unity announced plans to offer $500 million of convertible senior notes due 2030 in a private placement to institutional investors. The company also granted the initial purchasers a 13-day option to purchase up to an additional $75 million of the notes.
Unity expects to use the net proceeds from the offering to pay the cost of the capped call transactions, to repurchase for cash its 0% convertible senior notes due 2026 and for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses. 
The offering comes after Unity reported fourth-quarter financial results last week that came in ahead of analyst estimates. Unity reported revenue of $457 million versus estimates of $433.17 million, and an earnings loss of 30 cents per share versus estimates for a loss of 37 cents per share. 
Check This Out: <a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a>
Unity guided for first-quarter revenue of $405 million to $415 million versus estimates of $439.54 million. Despite the soft guidance, multiple analysts raised price targets on the stock following the print. 
Barclays maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Equal-Weight rating</a> and raised its price target from $18 to $26, Needham maintained a Buy rating a raised its price target from $26 to $33, Wells Fargo raised its target from $20 to $27 and Morgan Stanley maintained an Overweight rating and raised its target to $32. 
Unity said it had approximately $1.53 billion in cash, cash equivalents and restricted cash as of Dec. 31. 
U Price Action: <a href="http://benzinga.com/quote/u">Unity shares</a> were down 4.73% at $27.00 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Offerings

Unity Software Stock Is Moving Lower Monday: What's Going On?

&nbsp;Socket Mobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>), a leading provider of data capture and delivery solutions, is pleased to announce that its industrial and rugged scanning solutions, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4367973-1&amp;h=2482644287&amp;u=https%3A%2F%2Fwww.socketmobile.com%2Freaders-accessories%2Fproduct-families%2Fxtremescan&amp;a=XtremeScan">XtremeScan</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4367973-1&amp;h=1570778164&amp;u=https%3A%2F%2Fwww.socketmobile.com%2Freaders-accessories%2Fproduct-families%2Fdurasled&amp;a=DuraSled">DuraSled</a> families, respectively, are compatible with the new iPhone&#xAE; 16e.
The iPhone 16e is a durable, cost-effective device ideally suited for industrial environments. With an extra-long battery life, enhanced drop resistance, and the trusted iOS platform, it is expected to quickly become the go-to device for warehousing, logistics, manufacturing, transportation, and other demanding sectors. Socket Mobile industrial-grade scanning solutions combined with iPhones16e will enable employers to effectively deploy efficient and reliable data capture solutions.

SCKT

Socket Mobile  Announces That Its Industrial And Rugged Scanning Solutions, XtremeScan And DuraSled Families, Respectively, Are Compatible With The New iPhone 16e

Citizens Capital Markets analyst Nicholas Jones reiterates Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Market Outperform and maintains $6100 price target.

BKNG

Citizens Capital Markets Reiterates Market Outperform on Booking Holdings, Maintains $6100 Price Target

Barclays analyst Michael Leithead maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Equal-Weight and lowers the price target from $23 to $19.

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $19

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has seen a 19% decline over the past month, but traders are positioning for <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions">a potential rally</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,683.09</td>
<td>$323.5 billion</td>
<td>-4.4%</td>
<td>-3.1%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$95,838.47</td>
<td>$1.9 trillion</td>
<td>-0.1%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.47</td>
<td>$143.8 billion</td>
<td>-3%</td>
<td>-7.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Historically, ETH experiences a sharp wick within two weeks of a Bank of Japan (BoJ) rate hike, according to analyst Benjamin Cowen in a <a href="https://www.youtube.com/watch?v=p_2V0P_DJtA">podcast</a> published on Monday. 
He attributes this to the broader impact of monetary policy on risk assets.  In January 2025, the <a href="https://www.benzinga.com/news/econ-s/25/01/43183053/bank-of-japan-raises-interest-rates-to-pre-2008-levels-amid-trumps-tariff-uncertainties">BoJ hiked its interest rates</a> not seen since 2008 financial crisis. The next rate hike is likely expected in July with expectations at 0.75%, a Reuters poll <a href="https://www.reuters.com/markets/rates-bonds/boj-raise-rates-once-more-this-year-075-most-likely-q3-2025-02-20/#:~:text=In%20January%20the%20BOJ%20raised,achieving%20its%202.0%25%20inflation%20target.">estimated</a>.
Cowen also pointed out that ETH&#8217;s performance remains closely tied to Bitcoin—if BTC pumps, ETH/USD tends to follow. Also, the end of quantitative tightening, expected this summer, could be a major tailwind for ETH. For ETH/BTC to truly bottom, BTC would need to struggle in making new highs.
Meanwhile, Trader Tardigrade remains bullish on ETH at current levels, arguing that selling now is unwise.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> is literally holding up here &#x1f525; It&#39;s definitely not a good idea to sell at the current level.<a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a> <a href="https://t.co/ITKdPdStcD">pic.twitter.com/ITKdPdStcD</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1893998071799013833?ref_src=twsrc%5Etfw">February 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: IntoTheBlock data shows Ethereum's large transaction volume narrowed by 7.6%, while daily active addresses are up 3.8% in a single day. Exchanges netflows witnessed a significant 875.9% spike. Transactions greater than $100,000 have increased from 6,311 to 6,592.
Coinglass data shows Ethereum liquidations in the past 24 hours at $56.6 million, with long liquidations of $40.8 million.
Community News: The Pectra upgrade <a href="https://blog.ethereum.org/2025/02/14/pectra-testnet-announcement">launches</a> today on the Holesky testnet, with a mainnet rollout expected soon. This upgrade will enhance Layer-2 scaling and validator experience, further strengthening Ethereum's infrastructure. 
ETHDenver will take place from Feb. 27 until March 2. Crypto trader ElonMoney <a href="https://x.com/0xelonmoney/status/1893953203491774932">expects</a> bullish momentum, predicting key alpha leaks and potential Pectra-related announcements to drive ETH prices higher.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43901027/bybit-offers-140m-bounty-in-wake-of-14b-eth-hack-investigation-focuses-on-safe">Bybit Offers $140M Bounty In Wake of $1.4B ETH Hack, Investigation Focuses On Safe</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Ethereum Down 19% In A Month: Could Japan's Rate Hike Spark a Rally?

CENX

Century Aluminum shares are trading higher after BMO Capital upgraded its stock rating from market perform to outperform.

Press Releases

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Comments

ImmunityBio

空売り

ImmunityBio (NASDAQ:IBRX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル